-
Experts to explore future of emerging non-peptide, small molecule GLP-1 receptor agonists
An international panel will discuss small nonpeptide GLP-1 receptor agonists and what this research means for the outlook of diabetes treatment. Julio Rosenstock, MD, will present data from ACHIEVE-1, a trial for the oral GLP-1 receptor agonist orforglipron.
-
Researchers to present CV findings from SOUL trial of oral semaglutide in high-risk type 2 diabetes
Investigators, including John B. Buse, MD, PhD, will detail the key findings of a study to determine whether a new oral formulation of semaglutide is a safe and effective alternative to the injectable formulation.
-
Symposium will highlight major STRIDE forward in treating PAD alongside type 2 diabetes
Subodh Verma, MD, PhD, FRCSC, will share key results from a clinical trial using semaglutide in patients with type 2 diabetes and peripheral artery disease.
-
MariTide investigators will review trial data for monthly obesity treatment
Among the panelists, Ania M. Jastreboff, MD, PhD, will discuss results for participants without type 2 diabetes, and Harold Bays, MD, will discuss results for participants with the disease.
-
Symposium will discuss QWINT results that could signal paradigm shift in basal insulin dosing
Chantal Mathieu, MD, PhD, and other researchers will explain the latest data from a series of pivotal trials on once-weekly insulin efsitora alfa.
-
Researchers to share PATHWEIGH ‘roadmap’ for implementing weight management processes into primary care
PATHWEIGH focuses on reducing excess body weight and weight-related medical complications by providing patients with highly individualized care based on their needs, access, and preferences.
-
Investigators will present findings from treatment phase of CATALYST trial
Researchers, including Vivian Fonseca, MD, will return to the Scientific Sessions with new data on mifepristone use to treat people with hypercortisolism and difficult-to-manage type 2 diabetes.
-
Researchers to share weight loss results from bimagrumab and semaglutide combo
Steven B. Heymsfield, MD, and other panelists will explain insights into the treatment of obesity and overweight from BELIEVE.
-
Investigators to reveal full results from REDEFINE 1, 2 in Chicago
Melanie J. Davies, MB, ChB, MD, and other researchers will review data on combination therapy for weight loss using a fixed-dose combination of semaglutide and long-acting amylin analogue cagrilintide.